Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 2/20 | 0.41 |
| ▸ | CASP7 | P55210 | 2/20 | 0.41 |
| ▸ | HBB | P68871 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | NQO1 | P15559 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2255305 | 0.91 | ALDH1A1 (0.48) | ALDH1A1HSD17B10CYP3A4TDP1CASP1 | |
| SCHEMBL6163163 | 0.74 | CYP2A6 (0.37) | ALDH1A1HSD17B10CYP3A4TDP1CASP1 | |
| SCHEMBL457933 | 0.70 | CYP2A6 (0.33) | ALDH1A1HSD17B10CYP3A4TDP1CASP1 | |
| SCHEMBL457800 | 0.70 | CYP2A6 (0.42) | ALDH1A1HSD17B10CYP3A4TDP1CASP1 | |
| SCHEMBL456918 | 0.70 | CYP2A6 (0.42) | ALDH1A1HSD17B10CYP3A4TDP1CASP1 | |
| SCHEMBL456809 | 0.70 | CYP2A6 (0.42) | ALDH1A1HSD17B10CYP3A4TDP1CASP1 | |
| SCHEMBL1639049 | 0.70 | CYP1A2 (0.42) | CYP2A6CYP1A2ALOX12CA1CA2 | |
| SCHEMBL68114 | 0.70 | CYP2A6 (0.42) | ALDH1A1HSD17B10CYP3A4TDP1CYP2A6 | |
| SCHEMBL2003901 | 0.70 | HTR2A (0.39) | ALDH1A1HSD17B10CYP3A4TDP1CASP1 | |
| SCHEMBL315486 | 0.70 | CYP1A2 (0.45) | ALDH1A1CYP3A4CYP2A6CYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1716160-B1 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-29 | — | — | EP | claimed |
| US-20100048513-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2010-02-25 | — | — | US | claimed |
| US-7459444-B2 | Inhibitors of chymase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-02 | — | — | US | claimed |
| US-7138395-B2 | Interleukin-1β converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2006-11-21 | — | — | US | claimed |
| US-7041696-B2 | Interleukin-1β converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2006-05-09 | — | — | US | claimed |
| US-7001899-B2 | Interleukin converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2006-02-21 | — | — | US | claimed |
| US-6964948-B2 | Therapeutic peptide-based constructs derived from Domain II of bactericidal/permeability-increasing protein | XOMA TECHNOLOGY LTD. (BM) | 2005-11-15 | — | — | US | claimed |
| EP-1289954-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2005-09-14 | — | — | EP | claimed |
| EP-1289953-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2005-09-07 | — | — | EP | claimed |
| US-6936611-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-08-30 | — | — | US | claimed |
| WO-2003103677-A1 | DERIVATIVES OF AZEPINE AND THIAZERAN AS INTERLEUKIN CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-12-18 | — | — | WO | claimed |
| WO-2003104231-A1 | NOVEL INTERLEUKIN-1β CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-12-18 | — | — | WO | claimed |
| US-20030144195-A1 | Therapeutic peptide-based constructs | LITTLE ROGER G (US) | 2003-07-31 | — | — | US | claimed |
| US-6423825-B1 | OCTA-, NONA-, DECA- OR POLYPEPTIDE; HEPARIN BINDING AND NEUTRALIZATION; ANTIPROLIFERATIVE AGENTS OF ENDOTHELIAL CELLS; ANGIOGENESIS INHIBITORS | XOMA TECHNOLOGY LTD. (BM) | 2002-07-23 | — | — | US | claimed |
| EP-1196440-A2 | THERAPEUTIC PEPTIDES DERIVED FROM SUBSEQUENCES OF BPI | XOMA Technology Ltd. (US) | 2002-04-17 | — | — | EP | claimed |
| US-6355616-B1 | FUNGICIDE OLIGOPEOTIDES | XOMA (US) TECHNOLOGY LTD. | 2002-03-12 | — | — | US | claimed |
| WO-2001000655-A2 | THERAPEUTIC PEPTIDES DERIVED FROM SUBSEQUENCES OF BPI | XOMA TECHNOLOGY LTD. (US) | 2001-01-04 | — | — | WO | claimed |
| WO-2001000671-A1 | DERIVATIVE COMPOUNDS | XOMA TECHNOLOGY LTD. (US) | 2001-01-04 | — | — | WO | claimed |
| US-5804348-A | COLORLESS, METAL-FREE, IMPROVE CHARGE UNIFORMITY | EASTMAN KODAK COMPANY (US) | 1998-09-08 | — | — | US | claimed |
| US-5750305-A | Poly (2-(sulfonamidomethylene)-2-cyanoacetamido)phenyl acrylate! charge-control agents for electrostatographic toners and developers | EASTMAN KODAK COMPANY (US) | 1998-05-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048513-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, TPSAB1 | ALDH1A1 1606/4885HSD17B10 973/4885CYP3A4 939/4885 |
| US-20030144195-A1 | Therapeutic peptide-based constructs | LNPEP, SPPL2B, ENPEP | ALDH1A1 4802/4885HSD17B10 4348/4885CYP3A4 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.